PPARGC1A and diabetic kidney disease: Furthermore, p-MSCs can also effectively ameliorate podocyte injury and attenuate PINK1/Parkin-mediated mitophagy inhibition in DKD through the activation of the SIRT1-PGC-1α-TFAM pathway [269].